ID
45982
Beschrijving
Principal Investigator: Charles Keller, Children's Cancer Therapy Development Institute, Fort Collins, CO, USA MeSH: Glioma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000900 Diffuse Intrinsic Pontine Glioma (DIPG) is a universally fatal childhood cancer. Here, we performed a chemical screen in patient-derived DIPG cell cultures along with RNAseq expression analysis and integrated computational modeling to identify potentially effective therapeutic strategies. Panobinostat, among the more promising agents identified, demonstrated efficacy in pontine orthotopic xenograft models of both H3K27M and histone WT DIPG. These data suggest the potential utility of specific drug combinations and provides evidence of in vivo treatment efficacy of the multi-histone deacetylase inhibitor panobinostat. We are depositing to dbGaP deep sequencing whole exome data for 22 patient tumor samples and 13 matched normals, along with RNAseq data for 12 patient tumor samples and 6 normal pediatric brain tissue samples. In addition, we are depositing 22 RNAseq samples from DIPG cell lines before and after panobinostat treatment.
Link
Trefwoorden
Versies (1)
- 06-04-24 06-04-24 - Madita Rudolph
Houder van rechten
Charles Keller, Children's Cancer Therapy Development Institute, Fort Collins, CO, USA
Geüploaded op
6 april 2024
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000900 Functionally-defined Therapeutic Targets in DIPG
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with or without glioma and involved in the "Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma (DIPG)" project.
- Subject ID, sample ID, and sample use variable obtained from participants with or without glioma and involved in the "Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma (DIPG)" project.
- Sample ID, body site, analyte type, tumor status of sample, histological type, primary metastatic tumor, primary tumor location, and sequencing center of samples obtained from participants with or without glioma and involved in the "Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma (DIPG)" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with or without glioma and involved in the "Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma (DIPG)" project.
- Subject ID, sample ID, and sample use variable obtained from participants with or without glioma and involved in the "Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma (DIPG)" project.
- Sample ID, body site, analyte type, tumor status of sample, histological type, primary metastatic tumor, primary tumor location, and sequencing center of samples obtained from participants with or without glioma and involved in the "Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma (DIPG)" project.
C0680251 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,2])
C0205195 (UMLS CUI [1,3])
C0887950 (UMLS CUI [1,4])
C0373483 (UMLS CUI [1,5])